# China NMPA Product Recall - Compound Liver Extract Tablets (Capsules)

Source: https://www.globalkeysolutions.net/records/china_product_recall/changzhi-sanbao-biochemical-pharmaceutical-co-ltd/66cdefc6-557b-489d-b5ec-c4189b2fe8a1/
Source feed: China

> China NMPA product recall for Compound Liver Extract Tablets (Capsules) by Changzhi Sanbao Biochemical Pharmaceutical Co., Ltd. published December 25, 2015. Recall level: . The National Medical Products Administration (NMPA), through its State Food and Drug Administration 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Notice from the State Food and Drug Administration on Conducting Verification and Recall of Compound Liver Extract Tablets (Capsules)
- Company Name: Changzhi Sanbao Biochemical Pharmaceutical Co., Ltd.
- Publication Date: 2015-12-25
- Product Name: Compound Liver Extract Tablets (Capsules)
- Recall Reason: High levels of chromium were detected (the chromium content in the capsule shell met the regulations).
- Discovering Company: State Food and Drug Administration
- Manufacturing Company: Changzhi Sanbao Biochemical Pharmaceutical Co., Ltd.
- Summary: The National Medical Products Administration (NMPA), through its State Food and Drug Administration notice FDA Drug and Chemical Supervision [2015] No. 273, initiated urgent actions after detecting high chromium content in certain batches of Compound Liver Extract Tablets (Capsules). This issue, identified in 2015, specifically affected the product content, not the capsule shells. Four pharmaceutical companies—Changzhi Sanbao Biochemical Pharmaceutical Co., Ltd., Shandong Zhongtai Pharmaceutical Co., Ltd., Chongqing Shengao Biochemical Pharmaceutical Co., Ltd., and Boson Biopharmaceutical Group Co., Ltd.—were instructed to immediately cease production of these products. They are required to conduct thorough investigations into their production processes, raw material procurement, supplier audits, and sales channels. A complete market recall of all affected batches is mandatory, accompanied by public disclosure. Reports on sales channels were due by December 28, 2015, and comprehensive investigation results, including any legal actions, by January 10, 2016. Furthermore, provincial food and drug administrations were tasked with overseeing these recalls, enhancing surveillance and sampling of similar products from other manufacturers, and ensuring pharmaceutical businesses and consumers stop selling and using the recalled items while facilitating adverse reaction reporting.

Company: https://www.globalkeysolutions.net/companies/changzhi-sanbao-biochemical-pharmaceutical-co-ltd/51c6e306-5379-4ab1-964f-5120f87bb44a/